Effects of malaria and its treatment in early pregnancy

The Lancet Infectious Diseases

Volumn 12, Issue 5, 2012, Pages 359-360

  Desai, Meghna ^a,b   Dellicour, Stephanie ^a,c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ;

BIRTH DEFECT; DRUG EFFICACY; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; LETTER; MALARIA; MATERNAL AGE; MEDICAL INFORMATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SPONTANEOUS ABORTION; STILLBIRTH;

ANTIMALARIALS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PREGNANCY;

EID: 84860313263     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70345-0     Document Type: Letter

References (7)

1. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007, 7:93-104.
2. Ward SA, Sevene EJ, Hastings IM, et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007, 7:136-144.
3. Clark RL Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol 2009, 28:285-296.
4. Guidelines for the treatment of malaria 2010, World Health Organization, WHO, Geneva, (accessed Nov 24, 2011). http://www.who.int/malaria/publications/atoz/9789241547925/en/, 2nd Edn.
5. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population based study. Lancet Infect Dis 2011, published online Dec 13. 10.1016/S1473-3099(11)70339-5.
6. Dellicour S, ter Kuile FO, Stergachis A Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Medicine 2008, 5:e187.
7. Strom BL Pharmacoepidemiology 2000, John Wiley & Sons, Sussex.